News

Why Axalta Coating Systems is a High-Potential Growth Investment

Why Axalta Coating Systems is a High-Potential Growth Investment

Axalta Coating Systems: A Closer Look at Its Growth Potential

Growth investors want one thing: stocks that can lift a portfolio without adding unnecessary noise. That’s easier said than done. High-growth names often swing more than the market, and when expectations slip, so do prices. Still, you can narrow the field by focusing on a few reliable signals—projected earnings, how well a company turns assets into sales, and whether analysts are nudging estimates higher.

On those fronts, Axalta Coating Systems (NYSE: AXTA) is worth a look. The company pairs solid growth metrics with a favorable standing on growth-focused rankings. If you’re scanning for companies with momentum in the numbers, Axalta could earn a spot on your watchlist.

Earnings Growth That’s Set to Accelerate

For most investors, earnings growth is the heartbeat of a growth story. Double-digit gains tend to point to healthier business trends and, often, better stock performance. While Axalta’s historical Earnings Per Share (EPS) growth sits at 1.3%, the forward view matters more here. For this year, analysts expect EPS to climb 31.5%, well ahead of the industry’s 13.7%. That kind of gap hints at improving execution and a stronger profit engine.

Putting Assets to Work Efficiently

How efficiently a company turns assets into sales is another tell. The sales-to-total-assets (S/TA) ratio captures this, and Axalta’s current S/TA stands at 0.73. In plain terms, the company generates $0.73 in sales for every dollar of assets, modestly above the industry average of 0.7. It’s a small edge, but edges compound.

Layer on Axalta’s expected sales growth of 2.2% this year—also ahead of the industry’s 0.7%—and the picture sharpens. Better asset use plus faster top-line growth suggests a business that’s both disciplined and steadily expanding.

Estimates Are Moving the Right Way

Earnings estimate revisions often lead the stock, which is why they’re closely watched. When analysts raise the bar, it usually reflects rising confidence in near-term results. For Axalta Coating Systems, the Zacks Consensus Estimate for the current year has ticked up by 0.2% over the past month. It’s a measured move, but direction matters.

Bottom Line on Axalta’s Setup

Pulling it together, Axalta Coating Systems screens well for growth. It carries a Growth Score of B, signaling strength across key factors, and holds a Zacks Rank of #2, supported by positive estimate revisions. For growth-leaning investors, that blend—faster expected earnings, efficient asset use, and upward estimate momentum—makes Axalta a name to consider more closely.

None of this removes the usual risks that come with growth investing. But taken together, the markers here suggest Axalta Coating Systems has room to run if execution stays on track.

Frequently Asked Questions

Why does Axalta Coating Systems stand out as a growth pick?

It’s the combination: projected EPS growth of 31.5% for this year, which outpaces the industry’s 13.7%, alongside supportive metrics like efficient asset use and positive estimate revisions. Together, those point to improving fundamentals.

What does the 0.73 sales-to-total-assets ratio tell me?

For every $1 in assets, Axalta generates $0.73 in sales, a touch better than the industry’s 0.7. That suggests the company is putting its asset base to work slightly more effectively than peers.

How meaningful is a 0.2% rise in earnings estimates?

Revisions matter as a signal. A 0.2% month-over-month increase in the Zacks Consensus Estimate indicates analysts are growing more confident in Axalta’s near-term earnings power—incremental, but in the right direction.

What should I take from Axalta’s Growth Score of B and Zacks Rank #2?

A Growth Score of B reflects strength across growth drivers, while a Zacks Rank #2 points to a buy-rated setup based on earnings estimate trends. In short, both indicators lean positive.

What risks should I keep in mind with a growth name like Axalta?

Growth stocks can be volatile. If the expected 31.5% EPS growth or 2.2% sales growth doesn’t materialize, the stock can react. It’s worth weighing that against the current advantages—asset efficiency, estimate momentum, and a solid growth profile.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Nutex Health Wins Community Awards, Faces Big Risks

Updated Category News Views 11

Nutex Health Rides High on Community Approval You want to know how you earn the trust of a community? You deliver consistent healthcare that makes folks feel valued and respected. Nutex Health Inc. (NASDAQ:NUTX) didn't just toss a bone this quarter—they raked in a bunch of community honors that shout loud and clear: patients are at the heart of what they do. From...

Continue Reading
SIBIONICS Unveils GS3: AI Revolutionizes Glucose Monitoring

Updated Category News Views 27

An Unexpected Leap in Glucose Management When you think of the next big thing in medical technology, glucose monitoring probably doesn't pop into your head first. Yet here we are, SIBIONICS lighting up the Melbourne stage at that massive IDF-WPR joint congress. We're talking about AI-powered tech that isn't just fancy whirligigs, but something that could rock the medical...

Continue Reading
UCB's New U.S. Pact: Balancing Costs and Growth

Updated Category News Views 4

A New Chapter for UCB and U.S. Healthcare In the chess game of healthcare, UCB just made a strategic move by sealing a deal with the U.S. government. The Brussels-based biopharma powerhouse is doubling down on its commitment to make life-saving medicines more affordable in the States, while also pledging to a massive boost in domestic manufacturing. It's like hitting two...

Continue Reading
BNPL Summit 2026: Equipifi's Strategy for Holiday Success

Updated Category News Views 9

BNPL's Big Moment in Financial Institutions Well, the game's heating up in the Buy Now, Pay Later (BNPL) space, and here comes equipifi with a third day tagged onto their summit just for holiday strategies. It's like they spotted the tide and are making sure everyone has the right gear to ride it out. This virtual gathering from October 14-16 is shaping up to be a real...

Continue Reading
GABA Therapeutics' 2026 Annual Meeting Notice Rundown

Updated Category News Views 3

The paperwork is in, folks, and it's time for GABA Therapeutics to gather its clan of stockholders come September 10, 2026. Located in that corporate mecca, a.k.a. Newport Beach, California, motives are plain—vote and make decisions. What's on the Agenda? GABA Therapeutics, nestled in leafy Wilmington, is calling its shareholders to a significant gathering. It's not...

Continue Reading
BIOCORNEUM Adds Mineral SPF 30 to Scar Gel Lineup

Updated Category News Views 2

Scar Care Just Got an Upgrade with Mineral SPF 30 BIOCORNEUM's kicking it up a notch by introducing Mineral SPF 30 to their repertoire, a move that pivots their scar management tech firmly into the sun protection arena. If you've been around the block with skincare, you know scars need special treatment—and it ain't just about slapping on any old cream. With the...

Continue Reading
Insurance Reviews: Key to Adequate Protection?

Updated Category News Views 5

Why Insurance Reviews Shouldn't Be Ignored You ever think about how easy it is to get complacent with your insurance? Slap a policy together, lock it away in the vault of 'things I’ll deal with later,' and assume you're set. Well, according to Austin Budreau of Angola, Indiana—an insurance whiz doling out advice like hot coffee on a cold morning—that’s a risky...

Continue Reading
Factal's New Products Boost Security Team Insight

Updated Category News Views 3

Extending the Boundaries of Risk Intelligence When it comes to keeping a finger on the pulse of global events, a reactive approach just won't cut it anymore. Factal's latest offerings, Factal Advance and Factal Explorer, are set to reshape how security teams plan and respond to emerging threats and opportunities. These tools extend beyond real-time alerts, diving into...

Continue Reading
Optiv's Pivot: Forkan Named CRO Amid Cyber Surge

Updated Category News Views 28

Market Manoeuvres at Optiv with New CRO Well, here's something to chew over: Optiv Security, striding through the throngs of cybersecurity giants, made a serious play. Announcing veteran cutthroat Sean Forkan as Chief Revenue Officer, they're gearing up for turbocharged growth. It's a bold move, and puts the company on investors’ radar, especially with Forkan's track...

Continue Reading
Sun Life Adjusts Dividends for Preferred Shares, Eyes 2026

Updated Category News Views 0

Preferred Shares Get a New Look Sun Life Financial, folks, just threw a curveball into their dividend lineup with adjustments on their Series 10R and 11QR preferred shares. For those who’ve been in the trading pits long enough, this is the kind of news that can make or break your Thursday. Let’s cut through the noise and get to the meat of it all. TSX:SLF, if it’s...

Continue Reading

Top 5 Most Recently Viewed Articles

Public Policy Holding Company Launches IPO Roadshow Initiative

Updated Category News Views 120

Public Policy Holding Company Initiates IPO Roadshow Public Policy Holding Company, Inc. (NASDAQ: PPHC), recognized as a prominent global strategic communications firm, has embarked on a roadshow to promote its forthcoming initial public offering of 4,150,000 shares of common stock. This allocation includes 3,400,000 shares from PPHC and 750,000 shares from existing...

Continue Reading
Growth of Performance Food Group: A 5-Year Investment Story

Updated Category News Views 191

Growth of Performance Food Group: A 5-Year Investment Story Performance Food Group Co (NYSE: PFGC) has proven itself to be a strong player in the market over the last five years. With an impressive annualized return of 23.13%, the company has outperformed the overall market by a notable 9.43%. Currently, its market cap stands at an impressive $15.30 billion. Investment...

Continue Reading
XRP Price Trends: A Closer Look at Recent Market Changes

Updated Category News Views 453

XRP Price Trends Overview In the last 24 hours, the cryptocurrency market has seen XRP's price drop by 3.4%, bringing it down to $2.18. This decline is a continuation of its downward trajectory, having lost approximately 18.0% over the past week from a previous high of $2.69. Understanding the Price Movement The volatility of XRP can be better understood through price...

Continue Reading
Prudent Growth Partners Acquires Melbourne Plaza Retail Center

Updated Category News Views 183

Prudent Growth Partners Expands with Melbourne Plaza Acquisition Prudent Growth Partners, LLC, a well-known private equity real estate firm, has recently made headlines with its purchase of Melbourne Plaza, a retail center spanning 47,364 square feet. The acquisition price amounted to $7.85 million, marking a significant milestone for the firm. Mergers and Acquisitions in...

Continue Reading
Old Point Financial Achieves 52-Week Record Performance

Updated Category News Views 178

Old Point Financial Corporation Soars to New Heights Old Point Financial Corporation (OPOF) has recently made headlines as its stock surged to a remarkable 52-week high, now valued at $20.33. This achievement is not just a number; it symbolizes the growing confidence among investors regarding the company’s financial stability and future growth prospects. Over the past...

Continue Reading